» Articles » PMID: 18008331

Overexpression of E-cadherin and Beta-catenin Proteins in Metastatic Prostate Cancer Cells in Bone

Overview
Journal Prostate
Date 2007 Nov 17
PMID 18008331
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The expression of E-cadherin in the intercellular adhesion of metastatic prostate cancer cells in bone, which is the most prevalent site of metastatic growth, remains elusive.

Methods: The aim of the study was to compare the concurrent membranous expression of E-cadherin and beta-catenin proteins, the state which is known to be associated with the cellular adhesion function of E-cadherin, in prostate biopsy tissue specimens by immunohistochemical staining method. The expression patterns of E-cadherin or beta-catenin were classified as homogeneous (most cells exhibiting positively), heterogeneous (a few scattered patches of cells with positivity) or negative.

Results: Benign prostate hyperplasia cells exhibited homogeneous expression of both E-cadherin and beta-catenin in 9 of 11 (82%), whereas the primary prostate cancer cells were homogeneously positive for both proteins only in 4 of 22 (18%) of the cases. The results are similar to those reported in literature. However, in contrast to the primary cancer, a significantly increased frequency of the metastatic prostate cancer cells in bone exhibited homogeneous expression of E-cadherin and beta-catenin in 12 of 17 (71%) of the cases. A statistically significant association was observed between the overexpression of both proteins and the metastatic prostate cancer cells in bone (Fisher's exact P < 0.001).

Conclusions: The result of the study demonstrated for the first time that the membranous overexpression of E-cadherin and beta-catenin are significantly associated with the metastatic prostate cancer cells in bone and that the high frequency of expression suggest their involvement in the intercellular adhesion of the metastatic cells in bone.

Citing Articles

Overexpression of the mitochondrial anti-viral signaling protein, MAVS, in cancers is associated with cell survival and inflammation.

Trishna S, Lavon A, Shteinfer-Kuzmine A, Dafa-Berger A, Shoshan-Barmatz V Mol Ther Nucleic Acids. 2023; 33:713-732.

PMID: 37662967 PMC: 10468804. DOI: 10.1016/j.omtn.2023.07.008.


Cell Plasticity and Prostate Cancer: The Role of Epithelial-Mesenchymal Transition in Tumor Progression, Invasion, Metastasis and Cancer Therapy Resistance.

Papanikolaou S, Vourda A, Syggelos S, Gyftopoulos K Cancers (Basel). 2021; 13(11).

PMID: 34199763 PMC: 8199975. DOI: 10.3390/cancers13112795.


Clinicopathological significance of the EMT-related proteins and their interrelationships in prostate cancer. An immunohistochemical study.

Parol-Kulczyk M, Gzil A, Maciejewska J, Bodnar M, Grzanka D PLoS One. 2021; 16(6):e0253112.

PMID: 34157052 PMC: 8219170. DOI: 10.1371/journal.pone.0253112.


Prostate cancer metastasis and soy isoflavones: a dogfight over a bone.

Ajdzanovic V, Filipovic B, Miljic D, Mijatovic S, Maksimovic-Ivanic D, Miler M EXCLI J. 2019; 18:106-126.

PMID: 30956643 PMC: 6449674.


Epithelial-To-Mesenchymal Transition Markers and CD44 Isoforms Are Differently Expressed in 2D and 3D Cell Cultures of Prostate Cancer Cells.

Fontana F, Raimondi M, Marzagalli M, Sommariva M, Limonta P, Gagliano N Cells. 2019; 8(2).

PMID: 30754655 PMC: 6406374. DOI: 10.3390/cells8020143.